Track topics on Twitter Track topics that are important to you
June 18th 2010 Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce its Dyversity 2D image analyser and Dymension 2D analysis software are being used at US biopharmaceutical company, the Burzynski Research Institute (BRI), to determine the molecular effects compounds have on brain tumours.
Researchers at BRI are using Dyversity and Dymension to analyse Coomassie blue stained 2D gels of proteins derived from glioblastoma cells. Dyversity is also being utilised to image chemiluminescent Western blots of these proteins labelled with ECL. The information generated is helping to determine what effects different compounds have on proteins associated with brainstem glioma; an aggressive type of brain tumour and could lead to the introduction of novel treatments for this life threatening disease.
Dr Sonali Patil, a Scientist at BRI explained: “In 2007, we decided to use a proteomics approach to see what affects the anti-cancer compounds we are developing have at the molecular level. We saw a Dyversity at another medical institute in Houston and were so impressed with all the features it had for the price that we knew we had to have one.”
Dr Patil continued: “Since then we have used our own Dyversity in conjunction with the Dymension 2D analysis software to quantify spots on 2D gels because the two integrate well and the software layout makes this complicated analysis easy. We are extremely happy with the way it presents data and have even identified a couple of protein spots which look promising. Additionally, the technical support we have had from Syngene has been exceptional and I thoroughly recommend Dyversity and Dymension for 2D work.”
Paula Maia, Syngene’s Product Specialist stated: “We are proud to know our Dyversity 2D image analyzer and Dymension software are making a contribution to such important cancer research. The promising 2D results the BRI are seeing from the system and software combination shows scientists that Dyversity and Dymension are the complete package for rapidly producing high integrity data in any proteomics project.”
For Further Information Contact:
Jayne Arthur, Syngene, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727123 Fax +44 (0) 1223-727101
Email: email@example.com Web site: www.syngene.com
Sonali Patil Ph.D., Scientist, Department of Cell and Molecular Biology, Burzynski Research Institute, 12707 Trinity Drive, Stafford, Texas 77477, USA
Tel: + 281 240-5227 Fax: + 281 240-3306
Email: firstname.lastname@example.org Web: www.burzynskiresearch.com
Dr Sue Pearson, Director, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.
Tel/Fax +44 (0) 1462-635327 Email: email@example.com
Note to Editors
Syngene is a world-leading supplier of integrated imaging solutions for analysis and documentation of gel-based information. Syngene’s systems are used by more than 10,000 research organisations and over 50,000 individual scientists world-wide and include many of the world’s top pharmaceutical companies and major research institutes.
Syngene, founded in 1997 is a division of the Cambridge based Synoptics Group. The Group’s other divisions, Syncroscopy and Synbiosis, specialise in digital imaging solutions for microscopy and microbial applications respectively. Synoptics currently employs over 40 people in its UK and subsidiary operation in Frederick, USA.
About the Burzynski Research Institute
The Burzynski Research Institute (BRI) is a company based in Houston and Stafford, Texas, USA and carries out research and development of targeted gene therapies (antineoplastons or ANP) for the treatment of cancer. BRI was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name antineoplastons.
BRI believes ANP are useful in the treatment of human cancer, and is currently conducting Phase II clinical trials of ANP relating to the treatment of cancer. ANP have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services (“FDA”) or anywhere in the world.
In 2004, the FDA approved the designation of ANP as an “orphan drug” under the Orphan Drug Act of 1983, for the treatment of brainstem glioma. In 2008, ANP orphan drug designation by the FDA was extended to all glioma. It is estimated that in 2009 more than 21,000 men and women in the U.S., will be diagnosed with glioma, with prevalence estimated at approximately 84,000 cases.Jayne Arthur, Syngene, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK. Tel: +44(0) 1223-727123 Fax +44 (0) 1223-727101 Email: firstname.lastname@example.org Web site: www.syngene.com NEXT ARTICLE
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...